APBN

Asia-Pacific Biotech News

Two Medicines Recalled in China

Drugs found to cause adverse cardiac toxicity.

The National Medical Products Administration on 30 November 2018 announced an immediate ban of the production, marketing and use of composite terfenadine tablets and capsules in China.

The administration requests that all products should be recalled and destroyed under the supervision of local drug product management authorities before 31 December 2018.

The side effects, such as adverse cardiac toxicity, brought by the use of the two drugs outweigh the original benefits to cure colds and flu symptoms, according to the administration.

The approval documents for the production, marketing and use of the drugs have been revoked.

Companies manufacturing the two medical products are Livzon Pharmaceutical Group Co. in Zhuhai, South China’s Guangdong Province and CSPC Pharmaceutical Group in Shijiazhuang, North China’s Hebei Province, according to the administration information. [APBN]


Source: Global Times